Artwork

Contenido proporcionado por Hopkins Biotech Podcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Hopkins Biotech Podcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

Robert Hollingsworth: The Future of iPSC-based Cell Therapy Technology

45:34
 
Compartir
 

Manage episode 342868736 series 2788785
Contenido proporcionado por Hopkins Biotech Podcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Hopkins Biotech Podcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. Prior to Pfizer, he was Senior Director of Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs, and contributed to the approval of durvalumab. Before that, he held several R&D positions at GSK, Pharmacia, and Upjohn.

In this episode, we discuss Robert’s long career in biopharma, the platform technology being developed at Shoreline, and the role of strategic partnerships in early-stage development.

Hosted by Gustavo Carrizo and Joe Varriale.

  continue reading

84 episodios

Artwork
iconCompartir
 
Manage episode 342868736 series 2788785
Contenido proporcionado por Hopkins Biotech Podcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Hopkins Biotech Podcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. Prior to Pfizer, he was Senior Director of Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs, and contributed to the approval of durvalumab. Before that, he held several R&D positions at GSK, Pharmacia, and Upjohn.

In this episode, we discuss Robert’s long career in biopharma, the platform technology being developed at Shoreline, and the role of strategic partnerships in early-stage development.

Hosted by Gustavo Carrizo and Joe Varriale.

  continue reading

84 episodios

Todos los episodios

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida

Escucha este programa mientras exploras
Reproducir